WO2004061115A1 - Procede de production de $g(b)-glucane soluble a fonction immunologique et utilisation - Google Patents

Procede de production de $g(b)-glucane soluble a fonction immunologique et utilisation Download PDF

Info

Publication number
WO2004061115A1
WO2004061115A1 PCT/JP2003/016979 JP0316979W WO2004061115A1 WO 2004061115 A1 WO2004061115 A1 WO 2004061115A1 JP 0316979 W JP0316979 W JP 0316979W WO 2004061115 A1 WO2004061115 A1 WO 2004061115A1
Authority
WO
WIPO (PCT)
Prior art keywords
glucan
yeast
soluble
skin
acid
Prior art date
Application number
PCT/JP2003/016979
Other languages
English (en)
Japanese (ja)
Inventor
Shu Uemura
Teruhisa Kaneko
Chihiro Kaise
Robert Nakamura
John Vercellotti
Sharon Vercellotti
Original Assignee
Immudyne Japan Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immudyne Japan Inc. filed Critical Immudyne Japan Inc.
Publication of WO2004061115A1 publication Critical patent/WO2004061115A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds

Definitions

  • the present invention relates to a method of soluble-dulcan having a boat function and its use, and more particularly to a skin cosmetic having an excellent anti-aging function for skin and an S method of soluble / 3-glucan having an immune function suitable for use in the skin cosmetic.
  • Glucan is a polysaccharide having glucose as a clean position.
  • ⁇ - (1, 6) branched) 3- (1, 3) dulcan has been shown to enhance immune function and cholesterol-lowering ability.
  • Yeast combines at least three kinds of; 3-Dalcan; refractory 3-1, 3-D-Dalcan, rod-shaped / 3- 1, 6- D-Dalcan and ⁇ - (1, 6) branched ] 3— (1, 3) Glucan.
  • linear—1, 3-D-glucan, linear; 3--1, 6-D-dalcan does not activate macrophages, NK cells or neutrophils, or very little. is there.
  • the iS— (1, 6) branched / 3_ (1, 3) glucan as a polysaccharide species is a fraction that binds to 3 ⁇ 41 by linking ill with glucose units and (1 ⁇ 6) 3-glycosylated linkage. Consists of buying.
  • Yeast — (1, 6) branched / 3— (1, 3) dulcan is composed of several relatively short side chains (10% or 10%) fed by ⁇ - (1 ⁇ 6) glycosylated linkages.
  • (1 ⁇ 3) / 3 glycosylated linkages are the members (90% of which are above) and are mostly composed of members.
  • dulcan poly (1,3) —3—D-darcopyranosirile (1,6) -one-D-crecopyranose.
  • beta-glucans There are a variety of different types of beta-glucans. Those members' thread! ⁇ , Change with branch type, monomer type or substituent • It produces polysaccharides that exhibit very different physical and biological properties.
  • ⁇ -1,3 / 1,6—D-Dalcan is known to activate the invertebrate immune system as well as vertebrates.
  • 6 _D—Dalcan is most effective in activating macrophages, NK cells and neutrophils.
  • Yeast-derived; 3 glucan activates the immune system by binding to specific receptors on the cell membrane surface of macrophages.
  • Activated macrophages increase the production of various cytokines as well as their phagocytic and bactericidal capabilities.
  • yeast iS glucan Once the functions of macrophages and sputum cells are reduced, they can become responsible for the many beneficial effects of yeast iS glucan. For example, it is possible to improve the resistance to infections caused by infestation of bacteria, viruses, and protozoan parasites.
  • macrophages are also considered to be bad if NK cells function. In contrast, the ability of the host can be improved.
  • / 3— 1, 3/1, 6-D-Dalcan is a side chain iS_ 1, 3/1, 6- D-glucan or i3—1, 3—D_Dalcan and i3—1, The decision to determine whether it is a mixture of 6_D—Krecans or all of these 3—Klecans is (at least 3 of these 3/3 as yeast disliked. —Creates all glucan) ⁇ Not J ability, but the solubility is getting worse due to the variability of the number of / 3-1, 6 side chains.
  • 3-1, 3/1, 6- D-glucan only activates macrophages, so it is desirable to use a high yarn stringer / 3-1, 1, 3/1, 6- D-Dalcan .
  • insoluble i3-1-1, 3/1, 6- D-glucan is difficult to formulate parenterally or topically administered crane IJ, and it is also difficult to absorb percutaneously.
  • S3 ⁇ 4i, a soluble glucan has also been studied (Japanese National Publication No. 5-503952 and Japanese National Publication No. Hei 107-107702), but it is sufficient to have a soluble release or no immune function. In addition to these disadvantages, their use is limited to the medical use of wound healing.
  • An object of the present invention is to solve the above-mentioned problems of the technique.
  • the first object of the present invention is to provide an effective method for producing soluble i3-dalton having immune function.
  • a second object of the present invention is to provide a dermatological agent that is easy to handle and has an excellent anti-aging effect on skin.
  • soluble iS-glucan having an immune function based on the use of 3-dalcanase in the process of elaborating 3-dalcan derived from yeast (soluble yeast bases 1, 3Z1, 6- D—Dalcan. Yeast and Z or yeast extract).
  • the present invention includes a soluble / 3-glucan (soluble yeast, 1, 3/1, 6-D-Dal force, yeast and Z or yeast extract) that functions. It is in skin cosmetics that make it a tree.
  • soluble ttJ and “solubility” and means that it dissolves in water at room temperature (including colloidal form) on the shelf.
  • the difficulty of shelf may be 1% by weight of the cosmetic.
  • the obtained ⁇ -glucan-containing substance is dissolved (dispersed) completely in water or colloidally at a concentration of 1% by weight at room temperature.
  • Soluble yeast that enhances immune function in 3-glucan-containing products / 3-1, 3/1, 6-D-Dalton content is 95-; L 0 0% by weight
  • This soluble yeast i3_l, 3/1, 6-D-Glylecan preferably has a content of 2500-600.
  • the koji method of the present invention is sensitive to the use of
  • the yeast that produces purified i3-Dalcan can be used.
  • live yeast cells themselves, dried yeast powders and Examples include soluble yeast extracts obtained by solubilizing, extracting and purifying yeast cells under appropriate conditions such as autolysis, hot water extraction, mi iY, and enzyme.
  • Yeasts include yeast jS-1,3 glucan, yeast 0-1,3 / 1,6-D-glucan, and genus Saccharomyces such as brewer's yeast, baker's yeast, and obtain yeast extract.
  • Physics, ⁇ ⁇ 0 ⁇ , and biochemical methods can be used to break down the crumbling fungus.
  • commercially available yeast dry powder, yeast extract is easy to handle and readily available ⁇ (J. Above fermentation yeast extract usually contains protein, lipid, m organic acid, vitamin, amino acid, Nucleic acid-related quality is included.
  • Yeasts suitable for use in the present invention are i3-1-3 glucan, ⁇ -1, 3/1, 6-D-glucan having a molecular weight of 2500 to 400,000 or less, preferably 2500 to 60,000 koji, and beer fermentation. Examples include mothers, baker's yeast, and other genus Saccharomyce s, and J is 95% or more.
  • the insoluble '1' powder is washed with water and then treated with acid.
  • the powder is treated with 3-Dalcanase.
  • the fermented rice cake moon cake is treated with acid, washed at 7K, and then treated with sodium sootate. Wash the powder and treat with / 3-Dalcanase. Centrifuge the enzyme-treated mixture and remove the enzyme-treated powder. The supernatant is filtered through a membrane with an apparent cut capacity of 100,000 daltons and separated into a high "volume and low ⁇ *. After this, the substance is filtered through a membrane with 1000 daltons ⁇ ? 4, • Precipitate ⁇ -1,3 / 1,6-D-glucan and wash with absolute alcohol before drying in a vacuum oven.
  • Soluble j8—1, 3/1, 6-D-Dalcan that immunizes immune functions is S3 ⁇ 4t from yeast or other microorganisms containing / 3—1, 3/1, 6-D-glucan as follows be able to.
  • the t process described here relates to the production of ⁇ ⁇ ⁇ * soluble that retains macrophage activation ability (immune function)) 6-1, 1, 3/1, 6- D-crecan.
  • ⁇ Solubility to machine / 3— 1, 3/1, 6— D-Dalkan cocoons are the first component of / 3-Dalcan Threads containing alkali and acid soluble / 3-1, 3/1, 6-D-glucan (composed of fermented Tsuruta cysts yeast wall)! ! Process Xiemoto. This allows for the action of the enzyme; 3-Dalkane is obtained. After this treatment, the dissolved; 8-1,3X1,6-D-Dalcan is purified by enzymatic hydrolysis with; 3-Dalcanase. Here, the impurity ⁇ -glucan is removed.
  • the fermented tubule or fermented rice bud wall does not solubilize / 3—1, 3,1,6-D—glucan; To do.
  • an alkali metal or alkaline earth metal hydroxide for example, sodium hydroxide or potassium hydroxide of 0.05 to 1 ON is preferably used.
  • This step is performed at 4 ° C to 150 ° C, but preferably at about 80 ° C.
  • the process is always ij, or under pressure, with about 15 Pascal Z1 2 rc being particularly preferred.
  • the processing time is usually 10 minutes to 48 hours, but it depends on the type of alkali ⁇ and ffi iK.
  • the powder is separated from the aqueous solution by an appropriate means such as centrifugation, etc. 1 ".
  • This alkali treatment may be repeated once or several times. Wash the mulberry cell wall once or several times, then treat with acid such as «, formic acid, acetic acid, etc.
  • ⁇ ⁇ Acidic acid of 1 ⁇ 5, usually 4. (: ⁇ 1 5 0 ° Treat with C for 15 minutes to 48 hours, especially 3% vinegar ⁇ ⁇ solute ⁇ 85 ° C, preferably for 45 minutes and extract.
  • Insoluble raw material is a suitable process Remove TT from the solution by washing with water once or several times and then re-it ⁇ using appropriate means.
  • a soluble, ⁇ ⁇ ⁇ (2500 to 60,000)] 3-1, 3/1, 6_D-glucan having a function of ⁇ 3 ⁇ 4 can be obtained.
  • the conventional S8t ⁇ method has the problem that about 16% mannose and the like and impurities (cannot show transport function)) contain 3-Dalcan.
  • Soluble yeast) 3-1, 3/1, 6-D-glucan is 9
  • the skin cosmetic of the present invention contains soluble
  • the form of the skin cosmetic of the present invention is not particularly P-armed.
  • skin care products such as emulsion, cream, chemical ffi7_K, packs, facial cleansers, massages, body cosmetics and emulsifying fans, etc.
  • Products and quasi drugs Both are water-based That's right.
  • the dosage form of cosmetics is also arbitrary. For example, it is possible to take a solubilizing emulsifier form or a ⁇ form.
  • the soluble / 3-glucan may be added in an amount of 0.001 to 1%.
  • Soluble / 3—glucan distribution * is less than 0.0 0 1%, the immune activity improvement effect unique to soluble i3_Dalcan is not exerted in 3 ⁇ 41, and when it exceeds 1%, discoloration, May affect the stability of the system, which is not desirable.
  • ingredients to be formulated as (optional) ⁇ in the skin cosmetics of the present invention include oils, powders, surface active substances, low alcohol, high liver compounds, gelling agents, UV absorbing UV scattering agents, antioxidants
  • components commonly used in ordinary cosmetics such as lh dyes, preservatives, fragrances, and cosmetic ingredients, and these can be selected and used as long as the effects of the present invention are not impaired.
  • Liposome membrane shape / 3 ⁇ 4 base material is natural or synthetic such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, phosphatidylglycerol, phosphatidic acid, lysophosphatidylcholine, sphingomyelin, egg yolk lecithin, ⁇ a lecithin Phospholipids or silicon-added phospholipids, cholesterols such as cholesterol, cholesterol alkyl esters, phytosterols, phytosterol alkyl esters, glyceglycoglycolipids, asildarcosides such as cetylgalactoside, dialkyl-type synthetic surfaces Active I4, N-acylsphingosine or its sulfate ester, N-acylsphingoglycolipid, N-higher acyl dirtathion or a mixture of tt ⁇ S or more It is below.
  • Sea extinguisher water is a natural water rich in nutrients that is low in temperature, clean, and rich in nutrients.
  • the water intake depth is 2500-0500m, preferably 3200-0400m. Since deep ocean water contains numerous minerals, it has excellent moisture retention. 3 ⁇ 4Sf is excellent in raw life, which is thought to promote penetration of ingredients contained in cosmetics into the skin.
  • the distribution of the seabed water is usually 40 to 99%, preferably 50 to 60%.
  • the preferred optional self-synthesized component will be described more specifically.
  • the fats and oils include jojoba, oil, castor oil, olive oil, oil, coconut oil, palm oil, cacao oil, mink oil, turtle oil and the like.
  • hydrocarbons examples include I paraffin, petrolatum, microcrystalline wax, and squalene.
  • waxes examples include beeswax, lanolin, carnauba wax, and candelillaro.
  • Examples of lunar fatty acids include myristic acid, palmitic acid, stearic acid, oleic acid, isostearic acid, lauric acid and the like.
  • Synthetic esters include isopropyl myristate, isopropyl palmitate, butyl oleate, myristyl myristate, octyldodecyl myristate, propylene glycol monostearate,?
  • Examples include L myristyl L, isostearyl malate, glyceryl monostearate, and distearyl dimethyl ammonium chloride.
  • Oils, hydrocarbons, waxes, lunar fatty acids, synthetic esthetics are usually combined. It is blended at a ratio of ⁇ 5 Ow / w%.
  • alcohols examples include ethanol, 1,3-butylene glycol, propylene glycol, lauryl alcohol, cetanol, stearyl alcohol, and oleyl alcohol.
  • Alcohols are usually blended at a ratio of 0 to 1 OwZw%.
  • J includes glycerin fatty acid esters, sorbitan fatty acid esters, polyoxyethylene fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene alkyl ethers, coconut oil fatty acid monoethanolamide , Polyoxyethylene hydrogenated castor oil, sodium lauryl sulfate, polyoxyethylene darericyl pyrostearate, sodium alkylbenzene sulfonate, polyoxyethylene stearyl ether, dialkylsulfosuccinic acid, cetylpyridinium bromide, n-o chloride Decyltrimethylammonium, monoalkyl phosphate, N-acylsulfuric acid, N-acylglutamine, sucrose fatty acid ester, polyoxyethylene sorbitan monostearate And polyoxyethylene lauryl ether sodium sulfate, polyoxyethylene and lanolin.
  • the surface activity '14 ⁇ 1 is usually added at
  • thickener examples include strong lpoxyvinyl polymer, methylpolysiloxane, dextran, strong lpoxymethylcellulose, carrageenan, and hydroxypropylmethylcellulose.
  • the thickener is usually blended at a ratio of 0 to 1 wZw%.
  • humectant examples include glycerin, propylene glycol, 1,3-butylene glycol, puffer glutamic acid, acetyl tiltamic acid, hyaluronic acid, procyanidine and the like.
  • Moisturizer is usually. It is blended at a rate of ⁇ 5 w / w%.
  • preservatives examples include benzoic acid, salicylic acid, dehydroacetic acid or salts thereof, phenols of parabenzoic acid esters, and tricky sanhalocarban.
  • the preservative is usually blended at a ratio of 0 to 0 ⁇ 3wZw%.
  • Any fragrance may be used as long as it is generally used for cosmetics.
  • pigments examples include iron oxide, titanium dioxide, acid bffi-lead, kaolin, and talc.
  • the prescription is usually blended at a rate of 0 to 1 wZw%.
  • ⁇ IJ includes: Wheat oil, Vitamin A, Vitamin B 2, Vitamin E, Ascorbile acid mono-2-magnesium or sodium phosphate, D-Pantole alcohol, Dipotassium glycyrrhizinate, Dartathione, UV absorber, Chelating agent, Examples include plant extracts and microbial metabolite Z extracts.
  • W usually 0 to 3 w / w%.
  • Yeast, yeast extract, especially yeast cell wall —Dalcan has a high texture of ⁇ mi kinetic I ', so various cells and activities related to immune enhancement such as T cells and complement system It has been reported that it has a slight biological activity, while it has a brilliant biological activity, but on the other hand, there is almost no horn
  • Skin aging prevention cosmetics act mainly on rough skin (due to seasonal changes) and skin trauma caused by temporary deterioration of skin function. Drowning due to systemic malfunction requires an improvement in the balance of the person's entire biological system.
  • the skin cosmetics containing S-Dalcan (P-P) of the present invention acts on the wrinkle system and improves the balance of the biological system from the inside of the skin function. Of course, the effect on the human body is very sensible.
  • the skin cosmetics of the present invention have been used poorly solubilizing monoglucans that could not be formulated with water-soluble and transparent dosage forms of aqueous cosmetics (for example, chemicals can be formulated, and cosmetic cosmetic dosage forms
  • aqueous cosmetics for example, chemicals can be formulated, and cosmetic cosmetic dosage forms
  • the ij ability is used regardless of the choice, and is excellent in wrinkling on the skin, and exhibits excellent skin aging prevention effects on wisteria.
  • the rate of liposomes is dramatically improved, and it becomes possible for the first time to prepare a ribosome carrying more ⁇ -dulcan.
  • the amount of iS-Dalcan on the skin ? ! Improves MS MS and gains higher skin care effects (moisturizing, acupuncture, wrinkles, skin turnover, etc.).
  • the / 3-1, 1, 3/1, 6-D-glucan powder from this concession was washed with water with stirring for 15 minutes.
  • the fermented crane was treated with 10% 3% acetone in water at 37 ° C, koji was added, heated to 85 ° C, and stirred for 45 minutes. After washing the residue with water, it was treated with 15-75% of hypochlorous acid: * sodium acid. (Preferable conditions are a 20% concentration, a temperature of 4 to 150 ° C., more preferably 50 ° C. for 15 minutes to 48 hours.)
  • the straw was washed several times.
  • the dried precipitate is further purified by chromatography (affinity, dialysis, chromatography, etc.) or by dialysis using a filter that can select various 3 ⁇ 4.
  • the result of making 3 ⁇ 4 ⁇ containing 0.05% Taleton) in the morning is 8 weeks on the face of 100 women.
  • the present test was hired specialists as the ⁇ 1 is the result of Hosohito was monitored scratch mosquito ⁇ felt how after shelf
  • the method was prepared according to a conventional method and used as an emulsion.
  • the seawater layer water used here (reverse consideration) is the water that has been treated by retreating the ocean.
  • Example 3 Soluble glucan prepared by a method according to the method of Example 1 from about 800 to 100
  • FIG. 2 shows the results of examining the skin surface condition in a replica after 8 weeks of use and examining the improvement rate. (In addition, is as shown in Example 2.)
  • emulsion containing 0.05% of soluble 'I raw klecan 1 ⁇ 2H3 ⁇ 4 approximately 5 0 0 0 0 evening lens) prepared by the method of Example 1 was prepared.
  • Fig. 3 shows the results of a tape stripping test on the condition of the stratum corneum of the skin after using it for 8 weeks in the morning and evening, and examining the improvement rate. (The prescription is as shown in Example 2.) From the results of tape stripping, keratinocyte coverage was recognized before conversion in any of the cases, but 8 weeks after use. It turned out to be almost inconspicuous, and the stratum corneum was improved to a healthy state.
  • i3 ⁇ 4T indicates delamination of the stratum corneum, indicating that the skin condition is not healthy.
  • Soluble dulcan prepared by a method according to the method of Example 1 about 5 0 0 0 0 dart was prepared on the upper arm of 10 females for 4 weeks, and the skin turnover state was tested by the tape stripping method.
  • Figure 4 shows the results of the improvement rate. (The prescription is as shown in Example 2.)
  • the stratum corneum was peeled off in the state where the skin was previously roughened (color).
  • Fig. 1 is a graph showing the wrinkle improvement results (visually) of Example 3.
  • Fig. 2 is a graph showing the wrinkle improvement results (crane by replica) of Example 4.
  • FIG. 3 is a graph showing the improvement results of the stratum corneum in Example 5.
  • FIG. 4 is a draaf showing the improvement result of Kakuda rice cyst of Example 6.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de production efficace de β-glucane soluble à fonction immunologique et à action cosmétique, montrant un très bon effet d'empêchement de vieillissement de la peau. Un β-glucane soluble possédant une fonction immunologique (β-1,3/1,6-D-glucane soluble de levure, levure et/ou extrait de levure) est produit par utilisation de β-glucanase puis utilisé dans des préparations cosmétiques pour la peau.
PCT/JP2003/016979 2002-12-27 2003-12-26 Procede de production de $g(b)-glucane soluble a fonction immunologique et utilisation WO2004061115A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002380285A JP2004210895A (ja) 2002-12-27 2002-12-27 免疫機能を有する可能性β−グルカンの製造方法及び用途
JP2002-380285 2002-12-27

Publications (1)

Publication Number Publication Date
WO2004061115A1 true WO2004061115A1 (fr) 2004-07-22

Family

ID=32708430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/016979 WO2004061115A1 (fr) 2002-12-27 2003-12-26 Procede de production de $g(b)-glucane soluble a fonction immunologique et utilisation

Country Status (2)

Country Link
JP (1) JP2004210895A (fr)
WO (1) WO2004061115A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105310078A (zh) * 2007-05-08 2016-02-10 生物高聚物工程公司Dba生物治疗公司 粒状可溶的葡聚糖制备

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4979924B2 (ja) * 2004-11-16 2012-07-18 アサヒグループホールディングス株式会社 酵母水溶性多糖類の製造方法
JP4545063B2 (ja) * 2005-08-05 2010-09-15 キリンホールディングス株式会社 皮膚状態改善組成物
JP5153188B2 (ja) * 2007-03-30 2013-02-27 小林製薬株式会社 Ｔｈ１／Ｔｈ２バランス改善剤
KR100812129B1 (ko) 2007-09-07 2008-03-11 신석봉 비타민 씨와 수용성 베타 글루칸을 함유하는피부노화방지용 화장료조성물
JP5172930B2 (ja) * 2009-10-20 2013-03-27 国立大学法人佐賀大学 高粘性培養液の粘性低下方法
GB201501799D0 (en) * 2015-02-03 2015-03-18 Tate & Lyle Sweden Ab Methods of producing liquid compositions
JP6666084B2 (ja) * 2015-07-03 2020-03-13 フィンガルリンク株式会社 自然免疫力レベル評価方法および自然免疫力レベルの改善用パン酵母ベータグルカン含有製品
JP7181715B2 (ja) * 2018-07-13 2022-12-01 学校法人君が淵学園 トルラ酵母由来のβ－グルカン
CN112076209A (zh) * 2019-06-14 2020-12-15 青岛海洋生物医药研究院股份有限公司 一种β-葡聚糖组合物及其用途
WO2022244580A1 (fr) * 2021-05-21 2022-11-24 アサヒグループホールディングス株式会社 Immunostimulateur et procédé de production d'une composition de glucane
WO2023074808A1 (fr) * 2021-10-28 2023-05-04 三菱商事ライフサイエンス株式会社 Extrait de levure présentant une excellente texture

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466037A2 (fr) * 1990-07-06 1992-01-15 As Biotec-Mackzymal Procédé pour améliorer la résistance des animaux aquatiques aux maladies
JPH06340701A (ja) * 1993-06-01 1994-12-13 Nippon Oil Co Ltd 高分岐度β−グルカン、その製造法及び用途
WO1995030022A1 (fr) * 1994-04-29 1995-11-09 A/S Biotec-Mackzymal Traitement enzymatique des glycannnes
EP0875244A2 (fr) * 1997-05-02 1998-11-04 Ciba SC Holding AG Compositions microstructurées qui sont cosmétiquement acceptables
WO2002051361A1 (fr) * 2000-12-22 2002-07-04 Shu Uemura Cosmetics Inc. Produits de beaute pour la peau

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466037A2 (fr) * 1990-07-06 1992-01-15 As Biotec-Mackzymal Procédé pour améliorer la résistance des animaux aquatiques aux maladies
JPH06340701A (ja) * 1993-06-01 1994-12-13 Nippon Oil Co Ltd 高分岐度β−グルカン、その製造法及び用途
WO1995030022A1 (fr) * 1994-04-29 1995-11-09 A/S Biotec-Mackzymal Traitement enzymatique des glycannnes
EP0875244A2 (fr) * 1997-05-02 1998-11-04 Ciba SC Holding AG Compositions microstructurées qui sont cosmétiquement acceptables
WO2002051361A1 (fr) * 2000-12-22 2002-07-04 Shu Uemura Cosmetics Inc. Produits de beaute pour la peau

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105310078A (zh) * 2007-05-08 2016-02-10 生物高聚物工程公司Dba生物治疗公司 粒状可溶的葡聚糖制备
CN105310078B (zh) * 2007-05-08 2018-03-30 生物高聚物工程公司Dba生物治疗公司 粒状可溶的葡聚糖制备

Also Published As

Publication number Publication date
JP2004210895A (ja) 2004-07-29

Similar Documents

Publication Publication Date Title
KR102156898B1 (ko) 유산균발효 혼합물을 함유하는 피부 미백, 피부 보습, 항산화, 항염, 피부장벽 강화 및 피부흡수 기능을 개선한 섭취 가능한 화장료 조성물
WO2009139231A1 (fr) Extrait produit à partir d’une plante de la famille des orchidées, son procédé de production, et préparation pour application externe sur la peau comprenant l’extrait produit à partir de la plante de la famille des orchidées
WO2009084200A1 (fr) Préparation externe pour la peau, destinée à une peau acnéique
WO2012120290A2 (fr) Formulations cosmétiques
KR20110108686A (ko) 천연 원료 추출물을 포함하는 항산화제 및 이를 포함하는 사료, 식품, 또는 화장료 조성물
JP2004203811A (ja) 化粧料
EP1945179A1 (fr) Inhibiteur de la hyaluronidase contenant de l'acide poly-gamma-glutamique en tant que matiere active
EP0818200B1 (fr) Utilisation d'un polyholoside dans une composition destinée à favoriser la desquamation de la peau, et composition le comprenant
KR102006708B1 (ko) 산양삼을 이용한 비누 조성물 및 이를 포함하는 비누
WO2004061115A1 (fr) Procede de production de $g(b)-glucane soluble a fonction immunologique et utilisation
CN113384513A (zh) 一种酵母菌发酵产物滤液的制备方法及在化妆品中的应用
JP2006219432A (ja) 肌荒れ防止作用を有する組成物および化粧料、飲料
WO2014170595A1 (fr) Applications cosmétiques et pharmaceutiques de lactobacillus pentosus
WO2008032134A1 (fr) Procédé d'obtention de glucane de levure par autolyse de cellules de levure saccharomyces cerevisiae de boulangerie
CN107648087B (zh) 一种美白抗氧化护肤霜及其制备方法
JP6521210B2 (ja) セロビオースリピッドを含有することを特徴とするコラーゲン産生促進剤
KR101662272B1 (ko) 흑미의 배아와 미강 추출물 및 보리 추출물 혼합액을 유효성분으로 포함하는 화장료 조성물과 그의 제조방법
JP3184114B2 (ja) 保湿剤
JP6382815B2 (ja) 保湿剤
KR20210093662A (ko) 해조류 추출물을 유효성분으로 포함하는 화장료 조성물
KR20180082058A (ko) 천연 복합 추출물을 유효성분으로 포함하는 각질 박리용 화장료 조성물
KR101724529B1 (ko) 홍해삼 추출물을 흑효모 균사체로 발효한 홍해삼 흑효모 발효액을 포함하는 화장료 조성물
CA3210630A1 (fr) Biopolymeres a usage topique
KR20170005534A (ko) 천연배지를 이용한 잔나비걸상버섯 균사체 배양액을 함유하는 화장료 조성물
JP2009024075A (ja) 多糖体、その製造方法及びその用途

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase